Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Think Research Corporation THKKF


Primary Symbol: V.THNK

Think Research Corporation is a Canada-based company that offers digital health software solutions. It is a provider of cloud-based data, knowledge, and software solutions primarily delivered as software-as-a-service (SaaS) to healthcare delivery systems and the practitioners that they support. Its operations are organized into three lines of business: Software and Data Solutions, Clinical Research, and Clinical Services. Its SaaS solutions help patients find, navigate, and connect to health services across large governments and payer clients, while also ensuring safety for prescribed medications at pharmacies. Through its wholly owned subsidiary, BioPharma Services Inc., the Company provides research data and analysis derived from Phase I clinical trials, bioequivalence studies and bioanalytical services. Its clinics act as a test bed for its software and technology, transforming them with digital solutions that optimize clinical outcomes, streamline workflows, and optimize billing.


TSXV:THNK - Post by User

Comment by dt_coreon Jan 02, 2022 2:17pm
157 Views
Post# 34277472

RE:RE:Insider Selling

RE:RE:Insider Sellingmcappro, thanks for posting the SEDAR link. I would say that while its not uncommon to see automatic sales related to tax liabilities this tends to be elective for executivies/managers and firms with good governance policies recognize that such programs make limited sense for companies with low liquidity. Furthermore any insider that was gung ho on the firms prospects "should" have elected to pay tax liabilities in cash from other sources rather than sell stock in a relatively illiquid name because 1) buying shares and holding on to them makes more sense than acquiring more in public markets (a little bit of bidding pushed the price up significantly as we've seen recently), and 2) and share sales that are materially higher than daily average liquidity would push the stock downward as I would argue THNK insider selling has, which means insiders would have to sell even more stock to cover tax liabilities since those would be generated at time of issue.

I'm still on the sidelines for now but watching THNK closely at long term fundamentals (i.e. 2023+ rev, earnings, FCF, margin growth and potential to de-lever the balance sheet). Lots of beaten health tech / health related names such as WELL, LSPK, VIE, VHI etc. so many names of interest all requiring a catalyst for a share price rebound.



<< Previous
Bullboard Posts
Next >>